Infant Bacterial Therapeutics AB (STU:9IB) E10: €-0.65 (As of Mar. 2026)


STU:9IB Infant Bacterial Therapeutics AB STU:9IB
29 GF Score
Price €5.58
! 1 Warning Sign
View Full Analysis

What is Infant Bacterial Therapeutics AB E10?

Infant Bacterial Therapeutics AB STU:9IB -0.71% 29 E10 is €-0.65 as of Mar. 2026. GuruFocus rates STU:9IB with a GF Score™ of 29/100. The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Infant Bacterial Therapeutics AB's adjusted earnings per share data for the three months ended in Mar. 2026 was €-0.158. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €-0.65 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2026-06-28), Infant Bacterial Therapeutics AB's current stock price is €5.58. Infant Bacterial Therapeutics AB's E10 for the quarter that ended in Mar. 2026 was €-0.65. Infant Bacterial Therapeutics AB's Shiller PE Ratio of today is .


Infant Bacterial Therapeutics AB  (STU:9IB) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Infant Bacterial Therapeutics AB E10 Related Terms


Infant Bacterial Therapeutics AB E10 Historical Data

* Premium members only.

The historical data trend for Infant Bacterial Therapeutics AB's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Infant Bacterial Therapeutics AB E10 Chart

Infant Bacterial Therapeutics AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -0.63

Infant Bacterial Therapeutics AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 -0.64 -0.63 -0.65

STU:9IB vs VRTX, REGN, ALNY: E10 Comparison

For the Biotechnology subindustry, Infant Bacterial Therapeutics AB's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Infant Bacterial Therapeutics AB Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Infant Bacterial Therapeutics AB's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Infant Bacterial Therapeutics AB's Shiller PE Ratio falls into.


STU:9IB
29GF Score
Infant Bacterial Therapeutics AB STU:9IB
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Infant Bacterial Therapeutics AB E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Infant Bacterial Therapeutics AB's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.158/133.3862*133.3862
=-0.158

Current CPI (Mar. 2026) = 133.3862.

Infant Bacterial Therapeutics AB Quarterly Data

per share eps CPI Adj_EPS
201606 -0.272 101.019 -0.359
201609 -0.131 101.138 -0.173
201612 -0.237 102.022 -0.310
201703 -0.164 102.022 -0.214
201706 -0.257 102.752 -0.334
201709 -0.082 103.279 -0.106
201712 -0.145 103.793 -0.186
201803 -0.094 103.962 -0.121
201806 0.006 104.875 0.008
201809 -0.068 105.679 -0.086
201812 -0.215 105.912 -0.271
201903 -0.006 105.886 -0.008
201906 -0.063 106.742 -0.079
201909 -0.084 107.214 -0.105
201912 -0.235 107.766 -0.291
202003 0.009 106.563 0.011
202006 -0.237 107.498 -0.294
202009 -0.159 107.635 -0.197
202012 -0.233 108.296 -0.287
202103 0.004 108.360 0.005
202106 -0.257 108.928 -0.315
202109 -0.001 110.338 -0.001
202112 -0.141 112.486 -0.167
202203 -0.162 114.825 -0.188
202206 0.014 118.384 0.016
202209 -0.064 122.296 -0.070
202212 -0.325 126.365 -0.343
202303 -0.178 127.042 -0.187
202306 -0.220 129.407 -0.227
202309 -0.195 130.224 -0.200
202312 -0.272 131.912 -0.275
202403 -0.182 132.205 -0.184
202406 -0.281 132.716 -0.282
202409 -0.213 132.304 -0.215
202412 -0.218 132.987 -0.219
202503 -0.113 132.825 -0.113
202506 -0.129 133.699 -0.129
202509 -0.068 133.482 -0.068
202512 -0.131 133.386 -0.131
202603 -0.158 133.386 -0.158

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of €-0.65 mean?
Infant Bacterial Therapeutics AB (STU:9IB) has a E10 of €-0.65 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Infant Bacterial Therapeutics AB and its competitors.
Is Infant Bacterial Therapeutics AB's E10 too high?
Infant Bacterial Therapeutics AB's current E10 is €-0.65. Overall, Infant Bacterial Therapeutics AB has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Infant Bacterial Therapeutics AB's E10 compare to VRTX and REGN?
Infant Bacterial Therapeutics AB's E10 of €-0.65 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Infant Bacterial Therapeutics AB and its competitors. Infant Bacterial Therapeutics AB's current E10 is €-0.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Infant Bacterial Therapeutics AB stock overvalued right now?
Infant Bacterial Therapeutics AB (STU:9IB) has a current E10 of €-0.65. The current E10 is €-0.65. Infant Bacterial Therapeutics AB's overall GF Score™ is 29/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Infant Bacterial Therapeutics AB (STU:9IB), the current E10 is €-0.65 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Infant Bacterial Therapeutics AB Business Description

Other Exchanges IBT B:Sweden9IB:Germany
Address Katarina Bangata 70, Stockholm, SWE, 116 42
Infant Bacterial Therapeutics AB is a pharmaceutical company. Its purpose is to develop and commercialize drugs for diseases affecting premature babies. Its focus is on the drug candidate IBP-9414, whose development program is designed to show a reduced incidence of necrotizing enterocolitis (NEC) and improved gastrointestinal function (SFT) when treated with IBP-9414's active substance, Lactobacillus reuteri bacterial strain naturally found in human breast milk. Its portfolio also includes additional drug candidates, IBP-1016, IBP-1118, and IBP-1122. IBP1016, for the treatment of gastroschisis, is a life-threatening and rare disorder in which children are born with externalized gastrointestinal organs.
29GF Score

Get the complete analysis for STU:9IB

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.58
Price